2.335

3.19% -0.075

Inhibikase Therapeutics Inc (IKT)

Overview News Price History Financials Discussions Forecast Stock Split

Inhibikase Therapeutics Inc stock is traded at $2.335, with a volume of 290.41K. It is down -3.19% in the last 24 hours and up +10.58% over the past month. Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Previous Close:

$2.41

Open:

$2.41

24h Volume:

290.41K

Relative Volume:

0.35

Market Cap:

$325.12M

Revenue:

$79,600

Net Income/Loss:

$-48.26M

P/E Ratio:

-4.744

EPS:

-0.4922

Net Cash Flow:

$-28.24M

1W Performance:

-5.15%

1M Performance:

+10.58%

6M Performance:

+38.06%

1Y Performance:

+33.33%

1-Day Range:

$2.32

$2.42

1-Week Range:

$2.32

$2.515

52-Week Range:

$1.33

$2.53

Inhibikase Therapeutics Inc Stock (IKT) Company Profile

Name

Inhibikase Therapeutics Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

(302) 295-3800

Address

1000 N. WEST STREET, SUITE 1200, WILMINGTON

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

IKT's Discussions on Twitter

Compare IKT vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IKT Inhibikase Therapeutics Inc	2.33	336.28M	79,600	-48.26M	-28.24M	-0.4922
VRTX Vertex Pharmaceuticals Inc	515.76	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	805.65	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	990.87	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	211.83	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.63	39.31B	5.76B	514.49M	1.10B	4.4813

Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-04-26	Initiated	Ladenburg Thalmann	Buy
Jan-21-26	Initiated	BofA Securities	Buy
Dec-26-25	Initiated	H.C. Wainwright	Buy
Dec-11-25	Initiated	Cantor Fitzgerald	Overweight
Feb-12-25	Downgrade	H.C. Wainwright	Buy → Neutral

Inhibikase Therapeutics Inc Stock (IKT) Latest News

Aug 14, 2026

Perceptive group (IKT) discloses 6.9% Inhibikase stake through 10.3M warrant shares - Stock Titan

Aug 14, 2026

Nantahala reports 4.30% Inhibikase (IKT) stake across 5.81M shares - Stock Titan

Aug 14, 2026

Aug 13, 2026

Sands Capital group (NASDAQ: IKT) discloses 9.3% Inhibikase stake plus large warrants - Stock Titan

Aug 13, 2026

Oppenheimer Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $5 - Moomoo

Aug 13, 2026

Inhibikase Therapeutics Faces Rising BIOSECURE, China Supply Chain and Trial Risks That Could Disrupt Growth - TipRanks

Aug 13, 2026

Aug 12, 2026

Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 12, 2026

Aug 11, 2026

Is Inhibikase Therapeutics Inc (IKT) Positioned for Growth After Reporting $0.11 Loss? GF Score: 36/100 - GuruFocus

Aug 11, 2026

Inhibikase Q2 EPS of $(0.11) meets analyst consensus estimates - scanx.trade

Aug 11, 2026

Inhibikase Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 11, 2026

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity - GlobeNewswire

Aug 11, 2026

Aug 10, 2026

Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a shareEarnings Preview - TradingView

Aug 10, 2026

Aug 09, 2026

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Aug 09, 2026

Aug 02, 2026

Perceptive Advisors LLC Sells 3,106,568 Shares of Inhibikase Therapeutics, Inc. $IKT - MarketBeat

Aug 02, 2026

Aug 01, 2026

Inhibikase Therapeutics (IKT) Declines 4.4% as Stock Pressures Key $2.07 Support ZoneBreadth Thrust - dars.gov.et

Aug 01, 2026

Jul 31, 2026

Inhibikase Therapeutics, Inc. Revenue Breakdown – NASDAQ:IKT - TradingView

Jul 31, 2026

Inhibikase Wins FDA Orphan Status for PAH Drug Candidate - MyChesCo

Jul 31, 2026

18,030,000-share swap for warrant by Inhibikase Therapeutics, Inc. (IKT) - Stock Titan

Jul 31, 2026

H.C. Wainwright reiterates Inhibikase stock rating on FDA orphan drug status - Investing.com Canada

Jul 31, 2026

Jul 29, 2026

Inhibikase Therapeutics Q1 2026 Earnings: Narrower Loss Beats Estimates as Pipeline Progress Continues - dars.gov.et

Jul 29, 2026

ADAR1 Capital Management LLC Reduces Stock Position in Inhibikase Therapeutics, Inc. $IKT - MarketBeat

Jul 29, 2026

Jul 28, 2026

BlackRock (NYSE: BLK) discloses 5.9% holding in Inhibikase Therapeutics (IKT) - Stock Titan

Jul 28, 2026

Jul 27, 2026